The Journal of Korean Diabetes 2008;9(3):241-247.
메트포르민/글리벤클라미드 복합제의 유효성 및 안전성
백나나, 이우제, 이병두, 고경수
Effectiveness and Safety of Metformin/Glibenclamide Combination Tablets in Korean Type 2 Diabetic Subjects
Na Na Baek, Woo Je Lee, Byoung Doo Rhee, Kyung Soo Ko
Therapy with metformin/glibenclamide combination tablets is known to improve glycemic control and to increase compliance in patients with type 2 diabetes. The aim of this study is to prove the effectiveness and safety of metformin/glibenclamide combination tablets therapy in Korean type 2 diabetic patients. Methods: In this 12-week, prospective, multicenter, observational study, total 1,765 patients who were poorly controlled with diet, exercise, or oral hypoglycemic agent monotherapy received metformin/glibenclamide combination tablets therapy. The primary endpoint was the change of glycated hemoglobin (HbA1c) level from baseline to week 12. The changes of fasting and postprandial plasma glucose level and the safety profiles were also evaluated. Results: There was a significant reduction in HbA1c level (1.1%, P < 0.0001) after 12-week of metformin/glibenclamide combination tablets therapy. Fasting and postprandial plasma glucose levels were also significantly reduced (-42.7 mg/dL and -65.8 mg/dL, respectively, P<0.0001) after 12-week treatment. Treatment-related adverse events including hypoglycemia were subtle. Conclusion: Metfomin/glibenclamide combination tablets therapy provides effective glycemic control and safety profiles to Korean type 2 diabetic patients who were poorly controlled with diet, exercise or oral hypoglycemic agent monotherapy.
Key Words: Combination, Diabetes, Effectiveness, Glibenclamide, Metformin, Safety

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail:                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer